

Seres Therapeutics, Inc.
Form 4
June 29, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
AFEYAN NOUBAR

(Last) (First) (Middle)

1 MEMORIAL DRIVE, 7TH
FLOOR

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Seres Therapeutics, Inc. [MCRB]

3. Date of Earliest Transaction
(Month/Day/Year)
06/25/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☒ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☐ Form filed by One Reporting Person
☒ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.001 par value	06/26/2015		C		8,822,420	A	<u>(4)</u>	8,822,420	I	See Footnote <u>(1)</u>
Common Stock, \$0.001 par value	06/26/2015		C		2,205,603	A	<u>(4)</u>	2,205,603	I	See Footnote <u>(2)</u>
Common Stock, \$0.001 par value	06/26/2015		C		599,297	A	<u>(4)</u>	599,297	I	See Footnote <u>(3)</u>

Edgar Filing: Seres Therapeutics, Inc. - Form 4

Common
Stock,
\$0.001 par
value

3,055,556 I

See
Footnote
(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying Security (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title
Series A Convertible Preferred Stock	(4)	06/26/2015		C			6,105,362	(4)	(4)	Common Stock
Series A Convertible Preferred Stock	(4)	06/26/2015		C			1,526,338	(4)	(4)	Common Stock
Series A Convertible Preferred Stock	(4)	06/26/2015		C			599,297	(4)	(4)	Common Stock
Series A-2 Convertible Preferred Stock	(4)	06/26/2015		C			898,877	(4)	(4)	Common Stock
Series A-2 Convertible Preferred Stock	(4)	06/26/2015		C			224,719	(4)	(4)	Common Stock
Series B Convertible Preferred Stock	(4)	06/26/2015		C			1,818,181	(4)	(4)	Common Stock
	(4)	06/26/2015		C			454,546	(4)	(4)	

Series B
Convertible
Preferred
Stock

Common
Stock

Stock

Option (right to buy)	\$ 18	06/25/2015	A	15,000	(5)	06/24/2025	Common Stock
-----------------------------	-------	------------	---	--------	-----	------------	-----------------

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AFEYAN NOUBAR 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142	X	X		
Flagship Ventures Fund 2007, L.P. 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		
Flagship Ventures Fund IV, L.P. 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		
Flagship Ventures Fund IV-Rx, L.P. 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		
Flagship Ventures 2007 General Partner LLC 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		
Flagship Ventures Fund IV General Partner LLC 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		
KANIA EDWIN M JR 1 MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X		

Signatures

FLAGSHIP VENTURES FUND 2007, L.P., By: Flagship Ventures 2007 General Partner,
LLC, By: /s/ Noubar Afeyan, Name: Noubar B. Afeyan, Title: Manager 06/26/2015

__Signature of Reporting Person

Date

FLAGSHIP VENTURES 2007 GENERAL PARTNER, LLC, By: /s/ Noubar Afeyan, Name:
Noubar B. Afeyan, Title: Manager 06/26/2015

__Signature of Reporting Person

Date

FLAGSHIP VENTURES FUND IV, L.P., By: Flagship Ventures Fund IV General Partner,
LLC, By: /s/ Noubar Afeyan, Name: Noubar B. Afeyan, Title: Manager 06/26/2015

Edgar Filing: Seres Therapeutics, Inc. - Form 4

__Signature of Reporting Person	Date
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC, By: /s/ Noubar Afeyan, Name: Noubar B. Afeyan, Title: Manager	06/26/2015
__Signature of Reporting Person	Date
FLAGSHIP VENTURES FUND IV-RX, L.P., By: Flagship Ventures 2007 General Partner, LLC, By: /s/ Noubar Afeyan, Name: Noubar B. Afeyan, Title: Manager	06/26/2015
__Signature of Reporting Person	Date
FLAGSHIP VENTURELABS IV, LLC, By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar Afeyan	06/26/2015
__Signature of Reporting Person	Date
NOUBAR B. AFEYAN, PH.D, /s/ Noubar Afeyan	06/26/2015
__Signature of Reporting Person	Date
EDWIN M. KANIA, JR., /s/ Edwin Kania, Jr.	06/26/2015
__Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) Held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
 - (2) Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship Fund IV GP is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
 - (3) Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
 - (4) Each class of preferred stock converted into Common Stock on a one-for-one basis upon the listing of the issuer's securities on The NASDAQ Global Select Exchange and had no expiration date.
 - (5) Held by Noubar B. Afeyan, Ph.D. The option will vest as to 25% of the shares on June 25, 2016. The remainder of the shares will vest in 12 equal monthly installments.
 - (6) Held by Flagship VentureLabs IV LLC ("Flagship VentureLabs"). Flagship Fund IV is a member of Flagship VentureLabs and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship VentureLabs. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.